These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 3736679)
1. S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects. Rollema H; Feenstra MG; Grol CJ; Lewis MH; Staples L; Mailman RB Naunyn Schmiedebergs Arch Pharmacol; 1986 Apr; 332(4):338-45. PubMed ID: 3736679 [TBL] [Abstract][Full Text] [Related]
2. In vivo dopamine receptor binding studies with a non-radioactively labeled agonist, dipropyl-5,6-ADTN. Feenstra MG; Rollema H; Mulder TB; Westerink BH; Horn AS Life Sci; 1983 Mar; 32(12):1313-23. PubMed ID: 6403788 [TBL] [Abstract][Full Text] [Related]
3. In vivo displacement by 3-PPP enantiomers of N,N-dipropyl-5,6-ADTN from dopamine receptor-binding sites in rat striatum. Carlsson A; Löfberg L J Neural Transm; 1985; 64(3-4):173-85. PubMed ID: 4086990 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Van der Weide J; De Vries JB; Tepper PG; Horn AS Eur J Pharmacol; 1986 Jun; 125(2):273-82. PubMed ID: 3743637 [TBL] [Abstract][Full Text] [Related]
5. Similar binding of 3H-ADTN and 3H-apomorphine to calf brain dopamine receptors. Seeman P; Woodruff GN; Poat JA Eur J Pharmacol; 1979 Apr; 55(2):137-42. PubMed ID: 456412 [TBL] [Abstract][Full Text] [Related]
6. In vivo dopamine receptor agonist binding in rat brain: relation with pharmacological effects. Feenstra MG; Rollema H; Mulder TB; De Vries JB; Horn AS Eur J Pharmacol; 1983 Jun; 90(4):433-6. PubMed ID: 6684056 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of a chromanamine analogue (DP-6OH-3CA) of the selective presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin. Vermue NA; Dijkstra D; Horn AS J Pharm Pharmacol; 1988 Aug; 40(8):574-7. PubMed ID: 2907015 [TBL] [Abstract][Full Text] [Related]
8. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines. Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Timmermans PB; Wynberg H; Horn AS Eur J Pharmacol; 1986 May; 124(1-2):93-106. PubMed ID: 3720849 [TBL] [Abstract][Full Text] [Related]
9. Identification of dopamine "D3" and "D4" binding sites, labelled with [3H]2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, as high agonist affinity states of the D1 and D2 dopamine receptors, respectively. Urwyler S; Markstein R J Neurochem; 1986 Apr; 46(4):1058-67. PubMed ID: 2936868 [TBL] [Abstract][Full Text] [Related]
10. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin. Mulder TB; de Vries JB; Dijkstra D; Wiechers JW; Grol CJ; Horn AS Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544 [TBL] [Abstract][Full Text] [Related]
11. Striatal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics. List SJ; Wreggett KA; Seeman P J Neurosci; 1982 Jul; 2(7):895-906. PubMed ID: 6124583 [TBL] [Abstract][Full Text] [Related]
12. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes. Mulder TB; Grol CJ; Dijkstra D; Horn AS Eur J Pharmacol; 1985 May; 112(1):73-9. PubMed ID: 4018139 [TBL] [Abstract][Full Text] [Related]
13. [3H] 2-Amino-6,7-dihydroxy 1,2,3,4-tetrahydronapthalene (ADTN): a potential specific dopamine receptor ligand. Clement-Cormier Y; Abel M Res Commun Chem Pathol Pharmacol; 1978 Oct; 22(1):15-25. PubMed ID: 725314 [TBL] [Abstract][Full Text] [Related]
15. A prodrug of ADTN: selectivity of dopaminergic action and brain levels of ADTN. Horn AS; Kelly P; Westerink BH; Dijkstra D Eur J Pharmacol; 1979 Nov; 60(1):95-9. PubMed ID: 574829 [TBL] [Abstract][Full Text] [Related]
16. Binding of [3H]ADTN to rat striatal membranes. Templeton WW; Woodruff GN Biochem Pharmacol; 1982 Apr; 31(8):1629-32. PubMed ID: 6124259 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins. Weinstock J; Gaitanopoulos DE; Oh HJ; Pfeiffer FR; Karash CB; Venslavsky JW; Sarau HM; Flaim KE; Hieble JP; Kaiser C J Med Chem; 1986 Sep; 29(9):1615-27. PubMed ID: 2875183 [TBL] [Abstract][Full Text] [Related]
18. Ascorbic acid and membrane ageing: critical determinants of the in-vitro binding of [3H]ADTN to rat striatal tissue. Bradbury AJ; Costall B; Naylor RJ J Pharm Pharmacol; 1983 Nov; 35(11):738-45. PubMed ID: 6139456 [TBL] [Abstract][Full Text] [Related]
19. Resolution of 5,6-dihydroxy-2-(N,N-di-n-propylamino)tetralin in relation to the structural and stereochemical requirements for centrally acting dopamine agonists. Grol CJ; Jansen LJ; Rollema H J Med Chem; 1985 May; 28(5):679-83. PubMed ID: 4039369 [TBL] [Abstract][Full Text] [Related]
20. The significance of COMT activity in controlling dopamine agonist levels in brain and serum: studies with a prodrug and a metabolite of 6,7-ADTN. Rollema H; Westerink BH; Mulder TB; Dijkstra D; Feenstra MG; Horn AS Eur J Pharmacol; 1980 Jun; 64(4):313-23. PubMed ID: 7389825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]